Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03XWL
|
||||
| Former ID |
DIB009801
|
||||
| Drug Name |
Low dose ITI-007
|
||||
| Synonyms |
ITI-722; Low dose ITI-007 (oral, sleep maintenance insomnia/sleep disorder); Low dose ITI-007 (oral, sleep maintenance insomnia/sleep disorder), Intra-Cellular Therapies; 5-HT 2a receptor antagonist (oral, sleep maintenance insomnia/sleep disorders), Intra-Cellular Therapies
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Phase 3 | [1] | ||
| Company |
Bristol-Myers Squibb Co
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [2], [3] | |
| Sodium-dependent serotonin transporter | Target Info | Antagonist | [3] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04726:Serotonergic synapse | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP727:Monoamine Transport | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026498) | ||||
| REF 2 | Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. | ||||
| REF 3 | Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.